Please use this identifier to cite or link to this item:
|Title:||White matter hyperintensities on brain magnetic resonance imaging in people with epilepsy: a hospital-based study||Austin Authors:||Mao, YT;Goh, E;Churilov, Leonid ;McIntosh, A ;Ren, YF;O'Brien, TJ;Davis, S;Dong, Q;Yan, B;Kwan, P||Affiliation:||Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Departments of Medicine and Neurology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic, Australia
Florey Institute of Neuroscience and Mental Health, Melbourne, Vic, Australia
School of Mathematical and Geospatial Sciences, RMIT University, Melbourne, Vic, Australia
Melbourne Brain Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic, Australia
Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
|Issue Date:||6-Jun-2016||Date:||2016-06-06||Publication information:||CNS neuroscience & therapeutics 2016; 22(9): 758-763||Abstract:||AIMS: We aim to explore whether people with epilepsy have increased white matter hyperintensities (WMHs). METHODS: Eligible patients were categorized into newly diagnosed epilepsy (NE) and chronic epilepsy (CE); the latter were subdivided to those treated with enzyme-inducing antiepileptic drugs (EIAEDs) with or without non-enzyme-inducing antiepileptic drugs (NEIAEDs) and those with NEIAEDs only. WMHs were measured using age-related white matter changes (ARWMC) scale and compared between patients and healthy control group. Higher scores indicate greater WMH changes. The strengths of associations were estimated as incidence rate ratios (IRRs) with 95% confidence interval (CI). RESULTS: A total of 217 patients were included in the analysis, of whom 67 had NE, 45 had CE treated with NEIAEDs, and 105 had CE treated with EIAEDs. Age was positively associated with ARWMC score (IRR per year, 1.03; 95%CI, 1.03-1.04, P < 0.001). Compared with the healthy control group (n = 23), all patient groups had higher ARWMC score (P < 0.05). The difference was greatest in patients receiving EIAEDs (IRR, 2.13; 95%CI, 1.22-3.70, P = 0.007). CONCLUSIONS: WMHs tended to be observed in people with epilepsy, especially in those treated with EIAEDs. People with epilepsy with white matter changes should be evaluated for stroke risk, particularly if they are receiving EIAEDs.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/16035||DOI:||10.1111/cns.12571||Journal:||CNS Neuroscience & Therapeutics||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/27265831||Type:||Journal Article||Subjects:||Antiepileptic drugs
White matter hyperintensities
Magnetic Resonance Imaging
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 8, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.